At a glance

ClinicalIndex Comparison Record

Phase 2Completed

Drug / intervention

IdB 1016drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00055445

NCT00055445Phase 2Completed

Compare CT.gov

IdB 1016 in Hepatitis C

National Center for Complementary and Integrative Health (NCCIH)·interventional·Posted Mar 4, 2003·Updated Aug 18, 2006

In Brief

A Phase 2 clinical trial evaluating IdB 1016 for Hepatitis C, Chronic. Completed, across 1 site.

Detailed Summary

This study will measure the safety and tolerability of three different doses of IdB 1016 in patients with hepatitis C disease who have not responded to or are poor candidates for interferon-based therapies. NOTE: THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL CENTER IN SEATTLE

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHepatitis C, Chronic

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedMar 2003

Enrollment StartNov 2003

Study CompletionApr 2006

TodayJul 2026

First PostedMar 4, 2003

Enrollment StartNov 1, 2003

Study CompletionApr 1, 2006

TodayJul 2, 2026

Posted 23.3 years ago

Interventions

IdB 1016drug